Calliditas Therapeutics AB (publ)

NasdaqGS:CALT Stock Report

Market Cap: US$1.0b

Calliditas Therapeutics Management

Management criteria checks 3/4

Calliditas Therapeutics' CEO is Renee Aguiar-Lucander, appointed in May 2017, has a tenure of 7.08 years. total yearly compensation is SEK18.37M, comprised of 36.6% salary and 63.4% bonuses, including company stock and options. directly owns 1.2% of the company’s shares, worth $12.56M. The average tenure of the management team and the board of directors is 3.3 years and 5.1 years respectively.

Key information

Renee Aguiar-Lucander

Chief executive officer

kr18.4m

Total compensation

CEO salary percentage36.6%
CEO tenure7.1yrs
CEO ownership1.2%
Management average tenure3.3yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics

May 28

Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M

Aug 18

Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy

Jul 15

Calliditas submits nefecon marketing authorisation application to the EMA

May 28

Calliditas shares rise 10% as FDA grants priority review for Nefecon

Apr 28

Calliditas Therapeutics reports Q3 results

Nov 12

CEO Compensation Analysis

How has Renee Aguiar-Lucander's remuneration changed compared to Calliditas Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-kr525m

Dec 31 2023kr18mkr7m

-kr466m

Sep 30 2023n/an/a

-kr451m

Jun 30 2023n/an/a

-kr292m

Mar 31 2023n/an/a

-kr393m

Dec 31 2022kr13mkr6m

-kr412m

Sep 30 2022n/an/a

-kr628m

Jun 30 2022n/an/a

-kr608m

Mar 31 2022n/an/a

-kr576m

Dec 31 2021kr11mkr5m

-kr500m

Sep 30 2021n/an/a

-kr452m

Jun 30 2021n/an/a

-kr600m

Mar 31 2021n/an/a

-kr501m

Dec 31 2020kr7mkr3m

-kr433m

Sep 30 2020n/an/a

-kr286m

Jun 30 2020n/an/a

-kr198m

Mar 31 2020n/an/a

-kr54m

Dec 31 2019kr4mkr3m

-kr33m

Sep 30 2019n/an/a

-kr54m

Jun 30 2019n/an/a

-kr35m

Mar 31 2019n/an/a

-kr136m

Dec 31 2018kr4mkr2m

-kr132m

Compensation vs Market: Renee's total compensation ($USD1.75M) is below average for companies of similar size in the US market ($USD3.37M).

Compensation vs Earnings: Renee's compensation has increased whilst the company is unprofitable.

CEO

Renee Aguiar-Lucander (62 yo)

7.1yrs

Tenure

kr18,367,000

Compensation

Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...

Leadership Team

NamePositionTenureCompensationOwnership
Renee Aguiar-Lucander
Chief Executive Officer7.1yrskr18.37m1.2%
SEK 12.6m
Fredrik Johansson
Chief Financial Officer6.8yrsno data0.080%
SEK 835.1k
Lars Stubberud
Head of Technical Operations1.4yrsno datano data
Asa Hillsten
Head of IR & Sustainability1.4yrsno datano data
Brian Gorman
Group General Counsel1.4yrsno datano data
Sandra Frithiof
Head of Human Resources4.4yrsno datano data
Ann-Kristin Myde
Head of Clinical Development & VP of Project Management7.4yrsno datano data
Richard Philipson
Chief Medical Officer3.9yrsno datano data
Teona Johnson
Head of US Marketing3.3yrsno datano data
David Ferraro
Head of US Sales3.3yrsno datano data
Monika Tornsen
President of North Americaless than a yearno datano data
Christopher Ngai
Vice President of Market Accessno datano datano data

3.3yrs

Average Tenure

49yo

Average Age

Experienced Management: CALT's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Diane Parks
Independent Non-Executive Director5.1yrskr795.00k0.031%
SEK 330.1k
Elmar Schnee
Independent Chairman5.1yrskr1.74m0.086%
SEK 903.2k
Henrik Stenqvist
Independent Non-Executive Director2.1yrskr762.00k0.019%
SEK 195.3k
Elisabeth Bjork
Independent Director2.1yrskr587.00kno data
Jonathan Barratt
Member of Scientific Advisory Boardno datano datano data
Jürgen Floege
Member of Scientific Advisory Boardno datano datano data
Richard Lafayette
Member of Scientific Advisory Boardno datano datano data
Brad Rovin
Member of Scientific Advisory Boardno datano datano data
Vladimir Tesar
Member of Scientific Advisory Boardno datano datano data
Hérnan Trimarchi
Member of Scientific Advisory Boardno datano datano data
Hilde Furberg
Independent Non-Executive Director9.8yrskr731.00kno data
Heather Reich
Member of Scientific Advisory Boardno datano datano data

5.1yrs

Average Tenure

65yo

Average Age

Experienced Board: CALT's board of directors are considered experienced (5.1 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.